Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/oxfimm/iqaa001 http://scihub22266oqcxt.onion/10.1093/oxfimm/iqaa001 C7337782!7337782!33047740     free     free     free       Oxf+Open+Immunol 2020 ; 1 (1): ä Nephropedia Template TP {{tp|p=33047740|t=2020. Cholesterol-modifying drugs in COVID-19 |pdf=|usr=}}{{33047740}} gab.com Text Cholesterol-modifying drugs in COVID-19 JO: Oxf Open Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33047740 #FOAvip Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could influence the virus?host relationship. Cholesterol is essential for the assembly, replication and infectivity of enveloped virus particles; we highlight several cholesterol-modifying drugs with the potential to alter the SARS-CoV-2 life cycle that could be tested in in vitro and in vivo models. Although cholesterol is an essential component of immune cell membranes, excess levels can dysregulate protective immunity and promote exaggerated pulmonary and systemic inflammatory responses. Statins block the production of multiple sterols, oxysterols and isoprenoids, resulting in a pleiotropic range of context-dependent effects on virus infectivity, immunity and inflammation. We highlight antiviral, immunomodulatory and anti-inflammatory effects of cholesterol-modifying drugs that merit further consideration in the management of SARS-CoV-2 infection. Twit Text FOAVip Cholesterol-modifying drugs in COVID-19 ????Oxf Open Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33047740 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33047740 #FOAvip English Wikipedia <ref>{{Cite pmid|33047740}}</ref> Cholesterol-modifying drugs in COVID-19 #MMPMID33047740 Schmidt NM; Wing PAC; McKeating JA; Maini MK Oxf Open Immunol 2020[]; 1 (1): ä PMID33047740show ga Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could influence the virus?host relationship. Cholesterol is essential for the assembly, replication and infectivity of enveloped virus particles; we highlight several cholesterol-modifying drugs with the potential to alter the SARS-CoV-2 life cycle that could be tested in in vitro and in vivo models. Although cholesterol is an essential component of immune cell membranes, excess levels can dysregulate protective immunity and promote exaggerated pulmonary and systemic inflammatory responses. Statins block the production of multiple sterols, oxysterols and isoprenoids, resulting in a pleiotropic range of context-dependent effects on virus infectivity, immunity and inflammation. We highlight antiviral, immunomodulatory and anti-inflammatory effects of cholesterol-modifying drugs that merit further consideration in the management of SARS-CoV-2 infection. äCholesterol-modifying drugs in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing